Verge Genomics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Series A
  • Investors
  • 25

Verge Genomics General Information

Description

Developer of a drug discovery platform intended to revolutionize the way drugs are discovered and developed. The company's platform utilizes machine learning to develop new therapeutics and is specifically designed for neurological diseases, can analyze thousands of datasets to identify new targets and predict effective drugs, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Primary Office
  • Two Tower Place
  • Suite 950
  • San Francisco, CA 94080
  • United States

Verge Genomics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Verge Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 30-Jun-2020 000.00 Completed Generating Revenue
4. Early Stage VC (Series A1) 25-Jan-2019 000.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Jul-2018 0000 000.00 0000 Completed Generating Revenue
2. Seed Round 28-Oct-2015 $4M $4.12M Completed Startup
1. Accelerator/Incubator 18-Aug-2015 $120K $120K 00.000 Completed Startup
To view Verge Genomics’s complete valuation and funding history, request access »

Verge Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A6 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A5 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 00,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
Series A2 1,698,104 $0.001000 6% $2.65 $2.65 1x $2.65 8.37%
Series A1 8,502,149 $0.001000 6% $3.31 $3.31 1x $3.31 34.94%
To view Verge Genomics’s complete cap table history, request access »

Verge Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform intended to revolutionize the way drugs are discovered and developed. The company
Drug Discovery
San Francisco, CA
27 As of 2021
000.00
00000000000 000.00

00000 00

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Cambridge, MA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

00 00000

nsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat null
0000 000000000
Guilford, CT
00 As of 0000
0000
000000000 - 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verge Genomics Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Relay Therapeutics Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
00 000000000000 Venture Capital-Backed Guilford, CT 00 0000 000000000 - 0000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 0000000000 000.00
00000000 Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
000000000 Formerly VC-backed Salt Lake City, UT 000 00000 00000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Verge Genomics Executive Team (8)

Name Title Board Seat Contact Info
Alice Zhang Ph.D Co-Founder & Chief Executive Officer
James Summers Ph.D Acting Chief Science Officer
Michelle Mighdoll Strategic Initiatives & Data Acquisition Executive
Jason Chen MD Co-Founder & Advisor
Ben Jackson JD Vice President of Operations & Finance
You’re viewing 5 of 8 executive team members. Get the full list »

Verge Genomics Board Members (4)

Name Representing Role Since
Dave Madge WuXi AppTec Board Member 000 0000
Emily Melton Verge Genomics Board Member 000 0000
Melanie Leitner Ph.D ALS Investment Fund Board Member 000 0000
Stephen Kanes Ph.D Self Board Member 000 0000
To view Verge Genomics’s complete board members history, request access »

Verge Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verge Genomics Investors (25)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DFJ Growth Venture Capital Minority 000 0000 000000 0
Fitz Gate Ventures Venture Capital Minority 000 0000 000000 0
ALS Investment Fund Venture Capital Minority 000 0000 000000 0
Andrew Jiang Angel (individual) Minority 000 0000 000000 0
Basis Set Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 25 investors. Get the full list »